表紙
市場調査レポート

Eiger BioPharmaceuticals, Inc.:製品パイプライン分析

Eiger BioPharmaceuticals, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 251663
出版日 ページ情報 英文 27 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
Eiger BioPharmaceuticals, Inc.:製品パイプライン分析 Eiger BioPharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日: 2015年08月12日 ページ情報: 英文 27 Pages
概要

Eiger BioPharmaceuticals, Inc.は米国に本社を置くバイオ製薬企業で、肝炎治療薬である抗ウイルス剤の研究開発を行っています。同社が開発をすすめる候補物質としてEBP921、EBP994といった肝炎デルタ型ウイルス(HDV)の複製化およびプレニル化阻害物質があげられます。

当レポートでは、Eiger BioPharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Eiger BioPharmaceuticals, Inc.の基本情報

  • Eiger BioPharmaceuticals, Inc.の概要
  • 主要情報
  • 企業情報

Eiger BioPharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

Eiger BioPharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Eiger BioPharmaceuticals, Inc.:パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Eiger BioPharmaceuticals, Inc.:薬剤プロファイル

  • EBP-921
  • lonafarnib
  • EBP-1597

Eiger BioPharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

Eiger BioPharmaceuticals, Inc.:開発休止中のプロジェクト

Eiger BioPharmaceuticals, Inc.:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07501CDB

Summary

Global Markets Direct's, 'Eiger BioPharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Eiger BioPharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eiger BioPharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Eiger BioPharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Eiger BioPharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Eiger BioPharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Eiger BioPharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Eiger BioPharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Eiger BioPharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Eiger BioPharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eiger BioPharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Eiger BioPharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Eiger BioPharmaceuticals, Inc. Snapshot
    • Eiger BioPharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Eiger BioPharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Eiger BioPharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products Glance
    • Eiger BioPharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
  • Eiger BioPharmaceuticals, Inc. - Drug Profiles
    • EBP-921
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EBP-922
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lonafarnib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tipifarnib
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Eiger BioPharmaceuticals, Inc. - Pipeline Analysis
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Target
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Route of Administration
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Molecule Type
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Eiger BioPharmaceuticals, Inc. - Recent Pipeline Updates
  • Eiger BioPharmaceuticals, Inc. - Dormant Projects
  • Eiger BioPharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Eiger BioPharmaceuticals, Inc., Key Information
  • Eiger BioPharmaceuticals, Inc., Key Facts
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Eiger BioPharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Eiger BioPharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Eiger BioPharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Eiger BioPharmaceuticals, Inc. - Phase II, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Target, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Eiger BioPharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Eiger BioPharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Eiger BioPharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top